Literature DB >> 7230854

Primary malignant lymphoma of the trachea. Report of a case successfully treated by primary end-to-end anastomosis after circumferential resection of the trachea.

M Maeda, Y Kotake, Y Monden, K Nakahara, Y Kawashima, H Kitamura.   

Abstract

A 67-year-old Japanese man with exertional dyspnea was found by laminagraphy to have tracheal obstruction. The stricture was localized at the cervical and mediastinal trachea and was 5.0 cm long on an x-ray film. Eight tracheal rings were successfully resected and the ends of the trachea were anastomosed. The lumen of the removed trachea was narrowed by intramural and intraluminal polypoid growth originating from the tracheal wall. Histologically, the tumor was diagnosed as a mixed type of malignant lymphoma. The patient had serum hepatitis postoperatively, but now he is living normally without any difficulty in respiration. No signs of recurrence have been seen in the 5 years, 4 months since the operation. From this experience, the rarity and the possibility of curative operation of this tumor are discussed.

Entities:  

Mesh:

Year:  1981        PMID: 7230854

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

Review 1.  Primary tracheal lymphoma: case report and literature review.

Authors:  Akiyoshi Takami; Hirokazu Okumura; Yoshinobu Maeda; Yoshihisa Kumano; Hidesaku Asakura; Makoto Oda; Kenji Omura; Shinji Nakao
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

2.  Primary B cell malignant lymphoma of the trachea.

Authors:  J Wiggins; E Sheffield; M Green
Journal:  Thorax       Date:  1988-06       Impact factor: 9.139

3.  Mucosa-associated lymphoid tissue lymphoma of the trachea associated with idiopathic pulmonary fibrosis: A case report and literature review.

Authors:  June Hong Ahn; Jin Hong Chung; Kyeong-Cheol Shin; Eun Young Choi; Hyun Jung Jin; Joon Hyuk Choi; Kwan Ho Lee
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.